Head of Compliance & Data Privacy

Why 75 top pharma execs are ditching fragmented marketing stacks. At the Doceree Makers Summit, leaders from Sanofi, Bristol Myers Squibb, Eli Lilly, and others backed a new pharma marketing operating model to replace fragmented legacy softwares. A coalition of 75 pharmaceutical brand, commercial, and agency executives publicly endorsed a new marketing operations platform, underscoring growing pressure across life sciences organizations to simplify fragmented commercial technology systems and improve omnichannel marketing execution.[1] The announcement was made during the inaugural Doceree Health Decode: The Makers Summit 2026 in New York, where senior leaders from companies including Sanofi, Bristol Myers Squibb,, Avalere Health, and Deerfield supported Daily Command, a platform developed by Doceree.[1] According to Doceree, the executives collectively oversee more than $40 billion in annual pharmaceutical brand spending and are advocating for a more unified operating model designed to replace multiple disconnected systems across commercial functions, including targeting, CRM, analytics, media planning, and medical-legal-regulatory review.[1] "This isn't a product launch. It's the industry deciding, in public, that it is done with the way things are," said Harshit Jain, MD, founder and global CEO of Doceree, in the release.[1] "When seventy-five of the people who actually run pharma's biggest brands stop asking their vendors to do better and start co-building the replacement themselves, that is not a market trend. That is a market correction." The endorsement reflects a broader shift in pharma marketing commercialization. While omnichannel engagement has become a strategic priority, many organizations continue to operate across fragmented technology environments that limit speed, coordination, and consistency in execution. Why is pharma moving past fragmented commercial tech stacks? The Doceree announcement arrives at a time when pharmaceutical companies are continuing to invest heavily in digital transformation initiatives, yet still struggle to operationalize omnichannel strategies at scale. A 2025 Boston Consulting Group analysis found that while 97% of biopharma and medtech leaders view omnichannel capabilities as critical to commercial success, most organizations continue to face structural and operational barriers that prevent full integration across systems and workflows.[2] The report also highlights a persistent gap between ambition and execution. Only 10% of organizations reported having fully integrated data platforms that support omnichannel engagement, while the remaining majority cited siloed systems as a significant constraint.[2] These fragmentation issues can result in duplicated effort across teams, inconsistent reporting metrics, and delays in campaign activation. Why is fragmentation a commercial execution risk? As pharmaceutical companies are increasingly expected to deliver personalized, compliant, and timely engagement across healthcare professionals, patients, and payers, operational inefficiencies are becoming more visible and consequential. When core commercial functions, such as marketing, analytics, field operations, and compliance, operate across disconnected tools, execution slows and coordination becomes more complex. Campaign insights may be delayed or inconsistent, while measurement frameworks can vary significantly between systems. The industry response has increasingly shifted away from simply "adding more tools" toward reevaluating the underlying operational architecture that connects them. How is Daily Command a unified operating layer? Doceree described Daily Command as a shift toward a unified workflow environment intended to consolidate fragmented commercial processes into a single interface.[1] The company characterizes the platform as a "system of work" designed to bring together campaign planning, activation, measurement, and optimization. Daily Command also integrates Doceree's Clinical Intent Suite, which the company says uses behavioral and prescribing-decision signals to inform healthcare marketing engagement strategies.[1] The initiative reflects a broader effort to address inefficiencies in commercial execution by reducing reliance on multiple standalone systems that require manual coordination and data reconciliation. Agency and consulting leaders involved in the announcement highlighted similar challenges in current commercial ecosystems, particularly the operational burden created by disconnected systems and fragmented decision-making workflows. "Every category-defining software company in enterprise has been built on the same insight: own the surface where the work actually happens. In pharma marketing, and especially in full-service agencies like Deerfield, that surface has never existed," said Bill Veltre, Deerfield's chief media officer, in the release. Rather than replacing existing tools entirely, the platform is positioned as a centralized operational layer intended to unify workflows while maintaining interoperability with external partners and technologies. What does this mean for the industry? The Doceree initiative reflects a broader industry shift from expanding fragmented marketing toolsets toward consolidating workflows into more unified platforms. Doceree said Daily Command will enter closed beta in June with five pharmaceutical manufacturers and agency partners, followed by a broader release in July.[1] The coordinated endorsement from senior pharma marketers highlights a clear industry concern: in commercial technology is becoming a structural challenge affecting speed, visibility, and execution across commercialization.

Avalere Health has launched its Japan office in Tokyo, led by industry veteran Junji Yokokawa. The move expands the global healthcare strategic partner's footprint into the Japanese domestic drug market, which is experiencing significant growth driven by oncology, diabetes, immunology and rare disease treatments. The new office offers integrated services combining market access, medical and marketing expertise to support biopharmaceutical companies throughout the product lifecycle. Unlike traditional agencies, Avalere Health Japan was designed from inception to provide end-to-end solutions for navigating Japan's complex regulatory, pricing and patient engagement landscape. CEO Amar Urhekar, who previously spent a decade in senior Asia-Pacific roles with McCann Healthcare Worldwide, said the expansion aligns with Avalere's commitment to reaching every patient possible globally.